187 related articles for article (PubMed ID: 38429929)
1. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice.
Schuster KH; Zalon AJ; DiFranco DM; Putka AF; Stec NR; Jarrah SI; Naeem A; Haque Z; Zhang H; Guan Y; McLoughlin HS
Mol Ther; 2024 May; 32(5):1359-1372. PubMed ID: 38429929
[TBL] [Abstract][Full Text] [Related]
2. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
[TBL] [Abstract][Full Text] [Related]
3. Pathogenetic Mechanisms Underlying Spinocerebellar Ataxia Type 3 Are Altered in Primary Oligodendrocyte Culture.
Schuster KH; Putka AF; McLoughlin HS
Cells; 2022 Aug; 11(16):. PubMed ID: 36010688
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL
Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063
[TBL] [Abstract][Full Text] [Related]
5. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
6. Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3.
Bushart DD; Zalon AJ; Zhang H; Morrison LM; Guan Y; Paulson HL; Shakkottai VG; McLoughlin HS
Cerebellum; 2021 Feb; 20(1):41-53. PubMed ID: 32789747
[TBL] [Abstract][Full Text] [Related]
7. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
8. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
9. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
10. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
[TBL] [Abstract][Full Text] [Related]
11. Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis.
Chakraborty A; Tapryal N; Venkova T; Mitra J; Vasquez V; Sarker AH; Duarte-Silva S; Huai W; Ashizawa T; Ghosh G; Maciel P; Sarkar PS; Hegde ML; Chen X; Hazra TK
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8154-8165. PubMed ID: 32205441
[TBL] [Abstract][Full Text] [Related]
12. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Da Silva JD; Teixeira-Castro A; Maciel P
Neurotherapeutics; 2019 Oct; 16(4):1009-1031. PubMed ID: 31691128
[TBL] [Abstract][Full Text] [Related]
13. Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3.
Schuster KH; DiFranco DM; Putka AF; Mato JP; Jarrah SI; Stec NR; Sundararajan VO; McLoughlin HS
Front Neurosci; 2023; 17():1118429. PubMed ID: 36875652
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.
Moore LR; Rajpal G; Dillingham IT; Qutob M; Blumenstein KG; Gattis D; Hung G; Kordasiewicz HB; Paulson HL; McLoughlin HS
Mol Ther Nucleic Acids; 2017 Jun; 7():200-210. PubMed ID: 28624196
[TBL] [Abstract][Full Text] [Related]
15. Planning Future Clinical Trials for Machado-Joseph Disease.
Saute JAM; Jardim LB
Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
Krauss S; Nalavade R; Weber S; Carter K; Evert BO
Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
[TBL] [Abstract][Full Text] [Related]
17. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
Paulino R; Nóbrega C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
[TBL] [Abstract][Full Text] [Related]
18. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
[TBL] [Abstract][Full Text] [Related]
19. miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3.
Nobre RJ; Lobo DD; Henriques C; Duarte SP; Lopes SM; Silva AC; Lopes MM; Mariet F; Schwarz LK; Baatje MS; Ferreira V; Vallès A; Pereira de Almeida L; Evers MM; Toonen LJA
Nucleic Acid Ther; 2022 Jun; 32(3):194-205. PubMed ID: 34878314
[TBL] [Abstract][Full Text] [Related]
20. Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem Cells.
Ou Z; Luo M; Niu X; Chen Y; Xie Y; He W; Song B; Xian Y; Fan D; OuYang S; Sun X
Biomed Res Int; 2016; 2016():6701793. PubMed ID: 27847820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
